R&D Update

Creating a valuable and differentiated Exosome Delivery Platform

Strategic update

Priority focus now on Exosome drug delivery technology & Partnerships Ophthalmology assets to be out-licensed

New Senior Appointment Strengthening Exosomes Expertise

11 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.

New CTX-iPSC platform data shows potential in Peripheral Nerve Repair

19 November 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that new data relating to its CTX-derived induced Pluripotent Stem Cell (“CTX-iPSC”) platform has been presented this week, showing their commercial potential for the development of mass-scale therapeutics for peripheral nerve repair.